PKO Investment Management Joint Stock Co Boosts Stake in Boston Scientific Corporation $BSX

PKO Investment Management Joint Stock Co grew its stake in Boston Scientific Corporation (NYSE:BSX) by 69.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,000 shares of the medical equipment provider’s stock after acquiring an additional 9,000 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Boston Scientific were worth $2,148,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Steph & Co. purchased a new position in Boston Scientific in the third quarter valued at about $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the 3rd quarter worth approximately $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC increased its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $30,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Down 2.0%

BSX stock opened at $95.67 on Tuesday. The company has a market capitalization of $141.82 billion, a P/E ratio of 51.16, a price-to-earnings-growth ratio of 1.73 and a beta of 0.67. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The firm’s fifty day simple moving average is $97.52 and its 200-day simple moving average is $100.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the company posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Friday, October 17th. Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a research note on Monday, January 5th. Royal Bank Of Canada upped their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $125.21.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.